Previous 10 | Next 10 |
Improving VBR performance numbers are discussed. 4 new buy signals are explained. Barnwell Industries is highlighted and analyzed in more detail. I have some good news to report. My VBR lists have outlined solid progress on the performance front. All 34 picks since incep...
Shares have fallen by 30% over 5 years and have risen by 15% in 2022. CNS specialist has a rich 30+ year history, varied approved product portfolio and deep pipeline. Qelbree launch in ADHD is looking successful out of the gate despite pandemic headwinds, with clear value proposit...
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2022 Earnings Conference Call August 4, 2022 16:30 ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Particip...
Supernus Pharmaceuticals press release ( NASDAQ: SUPN ): Q2 GAAP EPS of $0.14 misses by $0.15 . Revenue of $170.05M (+674.0% Y/Y) beats by $5.82M . Outlook 2022: Total revenues $640M - $680M. Consensus $674.55M. Operating earnings $20M - $40M ...
Second quarter 2022 total revenues of $170.1 million, a 20% increase compared to second quarter 2021 Second quarter 2022 GAAP operating earnings of $11.3 million; second quarter 2022 non-GAAP operating earnings of $37.6 million Qelbree ® continued its growth trajectory, w...
Supernus Pharmaceuticals' newly approved QELBREE indication is poised to enhance its revenues. Supernus' developing Parkinson's disease [PD] franchise, with its upcoming PDUFA, is an uncertain catalyst. After a mixed Q1, 2022, expect Q2 to be uneventful, with deals likely looming ...
ROCKVILLE, Md., July 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fina...
ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of...
BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based on its preferred valuation metric of free cash flow to enterprise value (FCF/EV) for those tr...
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler J...
News, Short Squeeze, Breakout and More Instantly...
Supernus Pharmaceuticals Inc. Company Name:
SUPN Stock Symbol:
NASDAQ Market:
Supernus Pharmaceuticals Inc. Website:
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supern...
2024-05-24 08:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...